Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy.

Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy.

Therapeutic inhibition of the miR-34 family (miR-34a,-b,-c), or miR-34a alone, have emerged as promising strategies for the treatment of cardiac pathology. However, before advancing these approaches further for potential entry into the clinic, a more comprehensive assessment of the therapeutic poten...

Full description

Bibliographic Details
Main Authors: Bianca C Bernardo, Xiao-Ming Gao, Yow Keat Tham, Helen Kiriazis, Catherine E Winbanks, Jenny Y Y Ooi, Esther J H Boey, Susanna Obad, Sakari Kauppinen, Paul Gregorevic, Xiao-Jun Du, Ruby C Y Lin, Julie R McMullen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24587330/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24587330/?tool=EBI

Similar Items